Compass Therapeutics reports secondary endpoint data from pivotal biliary tract cancer trial, shares stock drop

Compass Therapeutics announced new secondary‑endpoint results from its pivotal bispecific antibody trial in second‑line biliary tract cancer, a year after reporting a Phase 2/3 success.

The additional data did not match the optimism generated by the earlier primary‑endpoint readout, and the market reacted sharply, with the company’s shares falling sharply after the release.

Analysts note that the weaker secondary outcomes could delay further development milestones and may affect the company’s valuation as investors reassess the drug’s commercial potential.